Addendum
Empagliflozin (heart failure and preserved ejection fraction) - Addendum to Commission A22-39
Report documents
-
Addendum
Empagliflozin (heart failure and preserved ejection fraction) - Addendum to Commission A22-39
Dossier assessment
Indication:
Adults with symptomatic chronic heart failure with preserved ejection fraction
Result of dossier assessment:
Unchanged after addendum:
- Without type 2 diabetes mellitus and without chronic kidney disease or with/without type 2 diabetes mellitus and with chronic kidney disease: hint of non-quantifiable added benefit
- With type 2 diabetes mellitus and without chronic kidney disease: added benefit not proven
Additional information
Federal Joint Committee (G-BA)
2022-09-15 A G-BA decision was published.
Project details
- Project no.
- A22-86
- Commission
- Commission awarded on 09.08.2022 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Heart and circulation
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
Connected Projects
-
Dossier assessment
Empagliflozin (heart failure) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed